Literature DB >> 11203727

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt.

G D Johnston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11203727      PMCID： PMC1119357     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Orlistat associated with hypertension.

Authors:  M Persson; S Vitols; Q Y Yue
Journal:  BMJ       Date:  2000-07-08

Review 2.  Dieting to reduce body weight for controlling hypertension in adults.

Authors:  C D Mulrow; E Chiquette; L Angel; J Cornell; C Summerbell; B Anagnostelis; R Grimm; M B Brand
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

4.  Treatment with orlistat reduces cardiovascular risk in obese patients.

Authors:  J H Zavoral
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

5.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

Authors:  L Sjöström; A Rissanen; T Andersen; M Boldrin; A Golay; H P Koppeschaar; M Krempf
Journal:  Lancet       Date:  1998-07-18       Impact factor: 79.321

6.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272
  6 in total
  1 in total

Review 1.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.